StoxNATCO Pharma vs Rainbow Childrens Medicare: share price & financials comparison
NSE: NATCOPHARM vs RAINBOW · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
NATCO Pharma vs Rainbow Childrens Medicare at a glance
NATCO Pharma (NATCOPHARM) has a market capitalisation of ₹14,445 Cr, against ₹12,639 Cr for Rainbow Childrens Medicare (RAINBOW). Over the past year NATCO Pharma has returned -2.5%, compared with -10.4% for Rainbow Childrens Medicare. On valuation, NATCO Pharma trades at a lower P/E of 12.6 versus 43.2. Rainbow Childrens Medicare earns a higher return on equity (17.0% vs 12.4%). NATCO Pharma comes out ahead on size and valuation. Rainbow Childrens Medicare comes out ahead on profitability, growth and technicals. Across the scored metrics below, NATCO Pharma leads on 7 and Rainbow Childrens Medicare on 8. On StoxGud's 10-point checklist, NATCO Pharma scores 4/10 and Rainbow Childrens Medicare scores 7/10.
| Metric | NATCO Pharma | Rainbow Childrens Medicare |
|---|---|---|
| Size | ||
| Market cap | ₹14,445 Cr | ₹12,639 Cr |
| Revenue (latest FY) | ₹4,078 Cr | ₹1,703 Cr |
| Net profit (latest FY) | ₹1,418 Cr | ₹278 Cr |
| Valuation | ||
| P/E | 12.6 | 43.2 |
| P/B | 1.57 | 7.37 |
| Dividend yield | 0.62% | 0.24% |
| Profitability | ||
| Return on equity | 12.4% | 17.0% |
| Net profit margin | 32.8% | 15.2% |
| Operating margin | 30.2% | 31.0% |
| Growth | ||
| Revenue growth (YoY) | -44.7% | +23.2% |
| Net profit growth (YoY) | -57.0% | +9.1% |
| Revenue CAGR (multi-year) | +14.7% | +15.0% |
| Financial health | ||
| Debt to equity | 0.08 | 0.00 |
| Momentum | ||
| 1-month return | -0.4% | -2.1% |
| 1-year return | -2.5% | -10.4% |
| 3-year CAGR | +2.6% | +6.7% |
| 5-year CAGR | -1.5% | — |
| 10-year CAGR | +3.3% | — |
| Distance from 52W high | -33.1% | -22.2% |
| Technicals | ||
| RSI (14) | 62 | 49 |
| Price vs 200-day avg | -13.0% | -5.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | NATCO Pharma | Rainbow Childrens Medicare |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✗ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 4/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, NATCO Pharma or Rainbow Childrens Medicare?
NATCO Pharma has a market cap of ₹14,445 Cr and Rainbow Childrens Medicare has a market cap of ₹12,639 Cr as of 06 Nov 2026.
Which has a lower P/E, NATCO Pharma or Rainbow Childrens Medicare?
NATCO Pharma has the lower P/E: NATCO Pharma trades at 12.6 and Rainbow Childrens Medicare at 43.2.
Which gave better returns in the last year, NATCO Pharma or Rainbow Childrens Medicare?
NATCO Pharma did better: NATCO Pharma returned -2.5% and Rainbow Childrens Medicare returned -10.4% over one year.
Is NATCO Pharma or Rainbow Childrens Medicare a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist NATCO Pharma scores 4/10 and Rainbow Childrens Medicare scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.